The aim of the study was to investigate the possibility of dual modulation
of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic co
lorectal cancer. A total of 77 patients with measurable disease were includ
ed. UFT (300 mg/m(2)) was given with a fixed dose of l-leucovorin (22.5 mg
daily) and hydroxyurea (0.5 g daily) for 28 days followed by a 7 days' rest
period. Treatment continued until progression or unacceptable toxicity. Si
xty-three patients were evaluable for response. One patient (1.6%) had a co
mplete remission and 13 (20.6%) a partial response for an overall response
rate of 22.2%. The treatment was well tolerated. No significant bone marrow
depression occurred. Grade 2 gastrointestinal toxicity was recorded in 28.
5% of the patients, and grade 3 in 12.9%. The median time to progression wa
s 6.8 months and the median crude survival was 11 months. In conclusion, hy
droxyurea did not appear to increase either the response rate or the toxici
ty. Phase III trials along the same line cannot be recommended.